Compare Citius Pharmaceuticals Inc (CTXR) vs Macy's Inc (M) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Macy's Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $18.73M), while Macy's Inc trades at $24.57 (market cap $6.68B). The key difference: Macy's Inc is far larger — about 356.6× Citius Pharmaceuticals Inc's market cap, and Macy's Inc pays a 3.02% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | M | |
|---|---|---|
Market Cap | $18.73M | $6.68B |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $26.21 |
52-Week Low | $0.48 | $12.73 |
Enterprise Value | $14.95M | $10.50B |
Dividend Yield | — | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.
The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.
Macy's (M) trades at $25.40, up 1.07% daily, with a bullish technical signal and positive earnings momentum after beating estimates in three consecutive quarters. The stock shows attractive valuation with a P/E of 10.5 and P/S of 0.31, while recent news highlights institutional buying and turnaround progress under the 'Bold New Chapter' strategy.
Outlook is cautiously optimistic with potential upside to the $30 analyst high target, supported by cost discipline and store revamps. Risks include competitive retail pressures and consumer spending volatility, but solid cash flow and low debt provide stability. The stock offers value with a 2.94% net margin and 14.36% ROE.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Macy's Inc
Founded in 1858 and based in New York City, Macy's operates 570 stores under the Macy's nameplate, 58 stores under the Bloomingdale's nameplate, and 160 freestanding Bluemercury specialty beauty stores (as of the end of fiscal-year 2021). Macy's also operates e-commerce sites and licenses two Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances comprised 59% of Macy's 2021 sales.
Read more on M →
